SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -
- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -